Navigation Links
Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
Date:11/19/2010

LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company has initiated treatment of patients in a pivotal clinical study of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.  Based on a partnership agreement signed with Ipsen SA (Euronext: IPN; ADR: IPSEY) in January 2010, Inspiration has received a $50 million milestone payment by Ipsen.  In return, Inspiration has issued to Ipsen a note, which may be converted to Series C preferred stock, bringing Ipsen's fully diluted share ownership position in Inspiration to 34%.

Under the terms of the agreement, Inspiration in-licensed OBI-1 from Ipsen, and is responsible for the clinical development, regulatory approval and commercialization of the product.  Inspiration is developing OBI-1 for the treatment of individuals with acquired hemophilia A and individuals with congenital hemophilia A who have developed inhibitors against human FVIII.

Dr. Anne Greist, at the Indiana Hemophilia and Thrombosis Center, in Indianapolis, Indiana, stated, "Acquired hemophilia is a condition in which patients develop antibodies against their own coagulation factors.  Affecting men and women equally, acquired hemophilia can lead to a life-threatening crisis for patients.  Unfortunately, current therapies are often inadequate to stop these types of acute bleeding episodes, and new innovative therapeutic approaches are needed.  We are pleased to have been the first site in the U.S. to enroll a patient in the pivotal study of OBI-1, a promising and important new product candidate in the treatment of acquired hemophilia."

Michael Griffith, Ph.D., President and CEO of Inspiration, commented, "We are excited to report the initiation of our pivotal clinical trial of OBI-1, one of two product candi
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... DUBLIN, Feb. 15, 2011 Warner Chilcott plc (Nasdaq: ... and full year 2010 financial results prior to the market opening ... issuing a press release, the Company will host a conference call ... AM (Eastern Time) to review the results. To participate in the ...
... Boston Scientific Corporation (NYSE: BSX ) ... treat peripheral chronic total occlusions (CTOs).  These acquisitions add ... devices for lower extremity peripheral artery disease.   ... 2010 from S.I. Therapies, Ltd., based in Israel.  The ...
Cached Medicine Technology:Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 2Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 3Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 4
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers ... the University of Pittsburgh School of Medicine are leading a five-year, $5 million ... sub-Saharan Africa. , A cooperative agreement awarded by the U.S. Agency for ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2
... With changes in the nation,s healthcare system looming and overall ... for debut at the Wynn Las Vegas this November has ... into alternative careers. The Medical Fusion conference ( ... that is tapping into the growing frustration of physicians practicing ...
... Patient-360(TM) tool optimizes impact of patient education programs. ... For marketers in the pharmaceutical industry, building relationships ... Data Development Worldwide,s Patient-360(TM) market research tool allows ... the patient pathway and then to prioritize and ...
... staph bacteria is being transmitted between animals and ... News) -- Transmission of methicillin-resistant staphylococcus aureus (MRSA) ... the most common being infections of the skin, ... a review of clinical evidence. , "Pet owners ...
... succeed where others have failed , MONDAY, June 22 (HealthDay ... in the United States could prove to be the toughest ... can reach that long-elusive goal, it would not only guarantee ... history, experts say. , "Assuming that President Obama ...
... with Patient and Chamber , , ANAHEIM, Calif., June ... in technology for hyperbaric healthcare, today announced the availability of ... verification of all NFPA (National Fire Protection Association) ... to be fully integrated into any hyperbaric chamber. The new ...
... Meeting -- , , News Facts , , ... new report, IDC Health Insights , an advisory services ... ranked Oracle as the number one vendor for enterprise life sciences software ... Software Top 10 identifies the 10 leading enterprise and specialty software vendors ...
Cached Medicine News:Health News:Physician Dissatisfaction Leads to New Medical Conference 2Health News:Physician Dissatisfaction Leads to New Medical Conference 3Health News:Data Development Worldwide Helps Pharmaceutical Marketers Optimize Relationship Marketing to Patients 2Health News:A Pet's Bite Can Pass on MRSA 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 3Health News:Health-Care Reform Could Be Obama's Toughest Challenge 4Health News:Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 3
Acuity Astigmatism: Letter Acuity, Astigmatic Clock, Number Acuity, and Tumbling E Tests....
... laboratory analysis that measures a substance produced by ... Annual PSA testing is a safe and effective ... as prostate cancer. One BIOSAFE Collection Kit, ... BIOSAFE's CLIA Certified Laboratory, and review of results ...
Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
... from 800 to 40 seconds ... as 2 years of age ... left to right., ,Randot Preschool ... #1: 200 & 100 sec ...
Medicine Products: